Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy, Surgery, and Radiotherapy for PNET or Ewing's Sarcoma
NCT00002466Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 1990
- Primary completion
- May 2005
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, doxorubicin, vincristine, etoposide and ifosfamide in Peripheral Primitive Neuroectodermal Tumor (pPNET) and Ewing sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Response Rate and Event-Free Survival. Started May 1990; status: completed.
02
Drugs
cyclophosphamidedoxorubicinvincristineetoposideifosfamide
03
Conditions
Peripheral Primitive Neuroectodermal Tumor (pPNET)Ewing sarcoma
Beyond the preview
Go deeper on NCT00002466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002466.